GLP-1 Weight Loss and Muscle: The Lean-Mass Data

About a quarter to 40% of the weight lost on GLP-1 drugs is lean mass, similar to what dieting alone removes#

When people lose weight on semaglutide or tirzepatide, body scans show that most of the loss is fat. A substantial minority is lean mass: about 25% in the tirzepatide trial SURMOUNT-1 and about 40% in the semaglutide trial STEP 1, counted as lean share of the fat plus lean tissue lost. That share is not unusual. It is broadly similar to what calorie restriction without a drug produces, and in SURMOUNT-1 the placebo group lost fat and lean tissue in the same proportions as the drug group¹.

So "Ozempic melts muscle" overstates what the scans show. The more accurate version: large weight loss by any route takes some lean tissue with it, GLP-1 drugs produce large weight loss, and "lean mass" on a scan is not the same thing as muscle. Two levers you control, protein and resistance training, may shift how much lean tissue you keep. The evidence is strongest for training, and it comes from ordinary diets rather than GLP-1 trials.

This article assumes you've read the basics of how a deficit produces weight loss in our guide to calorie deficits. The protein targets themselves are covered in protein intake on GLP-1 medications. Here the focus is the measurements.

What the DXA substudies measured#

Both big trial programs ran body-composition substudies using DXA (dual-energy X-ray absorptiometry), a low-dose scan that splits the body into fat, bone mineral, and "lean soft tissue" (lean mass here excludes bone mineral).

SURMOUNT-1 (tirzepatide). Of 255 people enrolled in the substudy, 160 were analyzed, with all tirzepatide doses pooled. On tirzepatide, body weight fell 21.3%, fat mass 33.9%, and lean mass 10.9%. On placebo the falls were 5.3%, 8.2%, and 2.6%. In both groups, about 75% of the fat plus lean tissue lost was fat and 25% was lean mass, and that split held in most subgroups, including an exploratory subgroup aged 65 and over¹.

STEP 1 (semaglutide). 140 participants were scanned at the start and at week 68. Body weight fell 15.0% on semaglutide, fat mass 19.3%, and lean mass 9.7%. Because fat fell faster than lean tissue, the proportion of the body that was lean rose by 3.0 percentage points². The source linked here is a conference abstract, a lighter level of peer review than a full paper.

The SURMOUNT-1 paper puts the STEP 1 result on the same footing: about 10.4 kg of fat and 6.9 kg of lean mass lost on semaglutide, or roughly 60% fat and 40% lean¹. The two drugs were tested in different trials, so this is not a head-to-head comparison.

Trial substudy	Weight change	Fat mass change	Lean mass change	Lean share of fat + lean lost
SURMOUNT-1, tirzepatide (n=124)	−21.3%	−33.9%	−10.9%	~25% (reported)
SURMOUNT-1, placebo (n=36)	−5.3%	−8.2%	−2.6%	~25% (reported)
STEP 1, semaglutide (n=95)	−15.0%	−19.3%	−9.7%	~40% (as reported by Look et al.)

Both programs were funded by the drugs' manufacturers.

Lean mass is not muscle#

This distinction changes how the numbers read. DXA "lean mass" is everything that isn't fat or bone mineral: skeletal muscle, and also organs, skin, blood, and water, including the water stored in fat tissue itself. A 2024 review of lean-mass changes with GLP-1 therapies makes the point directly: changes in lean mass "may not always reflect changes in muscle mass," because the measure includes organs, bone, fluids, and water in fat tissue³.

When a lot of fat disappears, some of the "lean" loss is the water and supporting tissue that fat carried with it. Skeletal muscle loss may therefore be smaller than the lean-mass figure, though DXA alone can't say by how much.

The same review lays out how wide the reported range is. In some GLP-1 studies lean mass made up 40–60% of the weight lost; in others it was about 15% or less. The authors attribute the spread to differences in who was studied, which drug, other conditions, and how body composition was measured. Studies using MRI, which can image muscle directly, suggest the reduction in muscle volume is about what you would expect from the weight lost and the person's age. They also found less fat inside the muscle, which the authors read as an improvement in muscle quality³. One disclosure: one of the three authors lists an affiliation with a private company, AMRA Medical AB, alongside a university post.

Whether the loss matters#

Researchers weigh this differently, and it comes down to one question: does the lean tissue lost change what your body can do?

The reassuring side argues from function. SURMOUNT-1 participants on tirzepatide reported better physical functioning than those on placebo, and the lean share of weight lost was no larger in people over 65¹. The authors also note that diets tested in other studies, including very-low-calorie, low-carb, low-fat, and high-fiber diets, produced similar fat-to-lean ratios. A 2024 JAMA viewpoint by Conte, Hall, and Klein takes up the same question in its title, whether weight-loss-induced muscle loss is clinically relevant⁴.

The cautious side argues from risk in specific people. Neeland and colleagues note that older age and more severe disease raise the risk of sarcopenia, the age-related loss of muscle strength and function, and may affect who is a good candidate for these drugs³. A 25% lean share of a 20% weight loss means something different for a 35-year-old than for a frail 75-year-old who started with little muscle to spare.

What is still missing: large trials measuring strength, walking speed, and falls over years of treatment.

Beyond what fraction of the weight was lean, a practical question is whether you can still climb the stairs, carry the shopping, and get up from the floor.

The lever with the strongest evidence: resistance training#

No large trial has yet tested resistance training on top of semaglutide or tirzepatide with body composition as the outcome. The best evidence comes from ordinary calorie restriction. A 2018 meta-analysis of six randomized trials in older adults with obesity compared calorie restriction alone against calorie restriction plus resistance training, three times a week for 12 to 24 weeks. Adding training prevented about 93.5% of the lean-mass loss that dieting alone caused, roughly 0.8 kg of lean tissue kept (95% CI 0.36 to 1.27 kg). There was no significant difference in fat loss between the groups⁵.

Two caveats: these were older adults on ordinary diets, not people on GLP-1 drugs, and six trials is a small base. Still, the direction is consistent with the broader evidence in our piece on protein and muscle preservation while dieting: a deficit mostly reduces the building of muscle, and training is the signal that restarts it.

Training also answers the function question directly, because strength is what it builds. Our comparison of cardio vs weights for fat loss covers why lifting earns a place even when the scale doesn't reward it.

Protein: necessary, not sufficient#

Appetite suppression makes eating enough protein harder, not easier. The SURMOUNT-1 authors point to published nutrition guidance for people on these drugs, suggesting about 60–75 g of protein a day and up to 1.5 g per kg of body weight¹. Those figures come from expert guidance, not from a GLP-1 trial showing that this intake preserves muscle. Your clinician should set your own number, especially if you have kidney disease.

Adequate protein supports muscle preservation, and training adds the stimulus that protein works with. In practice:

Put protein first on a small plate. When appetite is low, the part of the meal you eat first is the part you are most likely to finish.
Lift two or three times a week, with progressive loads, the pattern in the trials above.
Watch for changes in function, not just weight. Stairs, carrying, and getting up from a chair are better signals than lean-mass percentages. Our guide to losing fat vs losing weight explains why the scale alone can't tell them apart.

FAQ#

What percentage of weight lost on semaglutide is muscle?#

Nobody has measured muscle precisely in the main trials. In the STEP 1 DXA substudy, lean mass fell 9.7% while body weight fell 15.0%, and a later analysis puts lean tissue at about 40% of the fat plus lean lost¹. Lean mass includes water and organs, so the true muscle share is likely lower.

Is muscle loss on tirzepatide worse than on a normal diet?#

Not on current evidence. In SURMOUNT-1, about 25% of weight lost was lean mass with both tirzepatide and placebo, and the authors note that several types of diet have produced similar proportions¹. Placebo participants also received lifestyle counselling, and muscle itself was not measured directly. Tirzepatide caused more total weight loss, so the absolute amount of lean tissue lost was larger.

Who should worry most about lean-mass loss on GLP-1 drugs?#

Older adults and people who are frail or already low in muscle, because they have less to lose before strength and mobility suffer. A 2024 review flags age and disease severity as factors that may affect who is a good candidate for these drugs³. That is a conversation to have with your prescriber.

Sources#

Source: BurnWeek — "GLP-1 weight loss and muscle: what lean-mass measurements show", https://burnweek.fit/blog/how-much-weight-lost-on-glp1-is-muscle/. Licensed CC BY 4.0: free to quote or reuse with a link to this page.

This article was researched and drafted with AI assistance and reviewed for accuracy by the BurnWeek team. It is general information, not medical advice. How we research and correct our articles →